تولید ضد vWF VHH

• 

  توسعه VHH های ضد vWF موثر

  دانشمندان از روش دیگری به نام کتابخانه های نمایش فاژ استفاده کرده اند. بنابراین آنها کتابخانه ای از VHH ها دارند که به ویروس های کوچکی به نام باکتریوفاژها متصل هستند. به این ترتیب، دانشمندان می توانند VHH هایی را انتخاب کنند که به مناطق خاصی از vWF متصل می شوند. پس از جداسازی و توصیف اینها Anti-HER2 VHH تولید، داروها سپس از نظر ایمنی و اثربخشی ارزیابی می شوند. تیم Yaohai همچنین با سایر گروه ها و شرکت های تحقیقاتی برای شناسایی VHH های اضافی و ارزیابی فعالیت آنها در مدل های حیوانی هموفیلی کار می کند. این همکاری برای افزایش عمق تحقیق حیاتی است.  

• 

  تحقیقات تولید ضد vWF VHH

  In a recent work, the scientists identified one of the most potent anti-vWF VHH and denominated it VHH-33. VHH-33 is able to effectively inhibit this process of vWF-induced platelet agglutination. In the lab and in mice with hemophilia A, it also helped break up blood clots while being relatively safe for the body — that is about as close to a rousing success as one might hope when testing therapies. Indeed, to understand how VHH-33 stops vWF and prevents its issues, the researchers examined VHH-33 more closely. 

• 

  عصر جدید در درمان هموفیلی

  There are also other research teams across the globe doing great work in this field. For instance, a team in Germany generated mouse that recognize an important part  of Bispecific VHH Production (which is essential for its binding to platelets) [21]. One of the VHHs they generated, L318, was particularly good at preventing vWF from going haywire without causing any other issues in rabbits.  

چرا Yaohai Anti-vWF VHH Production را انتخاب کنید؟

• سیستم کیفیت و انطباق با مقررات جهانی

  Yaohai BioPharma, a top 10 Microbial CDMO that integrates quality management and regulatory affairs. Our quality system that is compliant with current GMP standards as well as international regulations. Our team of regulatory experts is proficient in global regulatory frameworks to accelerate biological launches. We ensure traceable production procedures quality products, as well as conformity with the requirements of the Anti-vWF VHH Production and EU EMA. Australia TGA and China NMPA are also met. Yaohai BioPharma successfully passed an in-person audit conducted by a Qualified Person of the European Union (QP) to examine our GMP system and production facility. We also completed the initial certification audits of the ISO9001 Quality Management System and ISO14001 Environmental Management System.

• زنجیره تامین و قابلیت های تولید قوی

  Anti-vWF VHH Production is a Top 10 biotech company specializing in microbiological fermentation. We have built a modern facility with strong RD capabilities and modern manufacturing facilities. Five production lines for pharmaceuticals in line with GMP standards for microbial purification and fermentation along with two automated fill and finish lines for vials and cartridges and pre-filled needles are available. The fermentation scales available are 100L, 500L, 1000L, to 2000L. Specifications for filling vials range from 1ml up to 25ml. the pre-filled syringes and cartridge filling specifications cover between 1-3ml. The workshop for production is cGMP compliant, and guarantees a stable supply of commercial products and clinical samples. Our factory produces large molecules that are shipped around the world.

• تخصص حرفه ای و تجربه گسترده

  Yaohai Bio-Pharma is a leading microbial biologics CDMO. Our main focus has been the production of Anti-vWF VHH Production and therapeutics to treat pets, human and veterinary health. We have state-of-the-art RD platforms and manufacturing technology that cover the entire manufacturing process beginning with the development of microbial strains Cell banking, process and method development, through commercial and clinical manufacture that ensures the successful delivery of innovative solutions. Over time we've gained a vast knowledge of microbial-based bio processing. We have successfully completed more than 200 global projects, and help our clients with navigating the rules and regulations of the US FDA, EU EMA, Australia TGA, and China NMPA. We are able to react promptly to market demands and provide tailored CDMO services due to our experience and expertise.

• سفارشی سازی، کارایی و مقرون به صرفه بودن

  Yaohai Bio-Pharma is experienced in the development of microbial-derived biologics. We offer customized RD as well as manufacturing solutions, while making sure that there are no risks. We have worked on diverse modalities such as subunit-based recombinant vaccines, Anti-vWF VHH Production, cytokines, growth factors, single domain antibodies, enzymes, plasmid DNA, the mRNA, and other. We are experts in a variety of microorganisms, including yeast extracellular and intracellular secretion (yields up to 15g/L) as well as bacteria intracellular soluble and inclusion body (yields as high as 10g/L). We have also developed the BSL-2 fermentation platform to create bacteria-based vaccines. We have a track record of improving production processes, thereby increasing yields and decreasing costs. With a highly efficient technology team, we ensure timely and quality project delivery and bring your products to market faster.

دسته بندی محصولات مرتبط

• تولید پلاسمید AAV
• روش‌های تحلیلی برای DNA پلاسمید
• تولید باکتریوفاژ AP205 VLP
• تولید باکتریوفاژ Q VLP
• تولید واکسن کایمریک VLP
• تولید واکسن های کونژوگه VLP
• تولید واکسن DNA
• تخمیر E. coli برای تولید VLP
• تولید آگونیست GLP-1
• تولید آنالوگ GLP-1

چیزی را که به دنبالش هستید پیدا نمی کنید؟
برای دریافت محصولات بیشتر با مشاورین ما تماس بگیرید.